Ernexa Therapeutics Highlights Successful Pre-IND Meeting with FDA

Company's cell therapy for ovarian cancer advances toward clinical trials

Feb. 3, 2026 at 8:39am

Got story updates? Submit your updates here. ›

Ernexa Therapeutics, a biotech company developing novel cell therapies, announced that it recently participated in a Virtual Investor "What This Means" segment to discuss the company's successful Pre-IND meeting with the U.S. Food and Drug Administration. The meeting provided regulatory alignment on Ernexa's development strategy for its lead cell therapy, ERNA-101, clearing the path for the company to submit an Investigational New Drug application and initiate clinical testing in the second half of 2026.

Why it matters

Ernexa's synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies represent a novel approach to treating advanced cancer and autoimmune diseases. The successful Pre-IND meeting with the FDA is a significant milestone that demonstrates the viability of Ernexa's technology and brings the company one step closer to potentially bringing a new treatment option to patients.

The details

During the Virtual Investor segment, Sanjeev Luther, President & CEO of Ernexa, highlighted how the regulatory alignment from the FDA on the company's development strategy for ERNA-101 provides a clear pathway toward submitting an IND and initiating clinical testing. This reinforces that technology transfer for clinical-grade manufacturing is already underway, accelerating Ernexa's operational readiness and positioning the company to advance its synthetic, allogeneic iMSC therapies designed to target ovarian cancer and autoimmune disease.

  • Ernexa plans to submit an Investigational New Drug (IND) application and initiate clinical testing for ERNA-101 in the second half of 2026.

The players

Ernexa Therapeutics

A biotech company developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases.

Sanjeev Luther

President and CEO of Ernexa Therapeutics.

U.S. Food and Drug Administration (FDA)

The federal agency responsible for regulating and supervising the safety of food, drugs, and other products in the United States.

Got photos? Submit your photos here. ›

What they’re saying

“Regulatory alignment from the FDA on Ernexa's development strategy for its lead cell therapy, ERNA-101, provides a clear pathway toward submitting an Investigational New Drug application and initiating clinical testing in the second half of 2026.”

— Sanjeev Luther, President & CEO of Ernexa Therapeutics

What’s next

Ernexa plans to submit an Investigational New Drug (IND) application and initiate clinical testing for ERNA-101 in the second half of 2026.

The takeaway

Ernexa's successful Pre-IND meeting with the FDA represents a significant milestone in the development of its novel cell therapies for advanced cancer and autoimmune diseases. The regulatory alignment paves the way for the company to advance its lead candidate, ERNA-101, into clinical trials, bringing a potential new treatment option one step closer to patients.